|
Mr. Feinstein co-founded BioVentures Investors in 1999. He has advocated for, participated in and championed the biotechnology industry for over 26 years. Mr. Feinstein has advised a broad range of life science companies on public offerings, mergers, limited partnerships, private placements, and start-ups. He pioneered the approach of establishing valuation based on scientific and business achievements prior to product sales. Prior to co-founding BioVentures Investors, Mr. Feinstein founded the leading biotechnology communications firm, Feinstein Kean Healthcare. The firm was sold to the WPP group in 1999, after building a stellar reputation and a unique blend of services to support the development of biotech companies and the marketing of biopharmceutical products. Clients included Genzyme, Biogen, Vertex Pharmaceuticals, Amgen, Abiomed, Novartis, Sepracor and others. | 